neuroendocrine carcinomas

临床试验

计划入组 25 人 · 首次发布于 2019 年 10 月 10 日

终止

NCT07061080

Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab

计划入组 1 人 · 首次发布于 2025 年 7 月 11 日

终止

NCT03042780

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

计划入组 2 人 · 首次发布于 2017 年 2 月 3 日

药物

查看全部 55 →

Small Molecule

Approved

Lutetium Lu 177 dotatate(Lutathera)

相关疾病：Gastroenteropancreatic Neuroendocrine Tumors

C₆₅H₈₇LuN₁₄O₁₉S₂

Small Molecule

Investigational

Temoporfin(Foscan)

相关疾病：Advanced squamous cell carcinoma of the head and neck

C₄₄H₃₂N₄O₄

Small Molecule

Approved

Cisplatin(Platinol)

生产企业：App pharmaceuticals llc, Bedford laboratories div ben venue laboratories inc，另有 3 家

相关疾病：Advanced Ovarian Cancer, Ovarian Cancer Metastatic，另有 3 项

Cl₂H₆N₂Pt · Rx

机构

Crinetics

United States

资讯

查看全部 676 →

去年

BI 764532 T-Cell Engager Shows Promise in DLL3-Positive Neuroendocrine Carcinomas with 29% Response Rate

去年

DLL3-Targeted Therapies Show Promise in Neuroendocrine Prostate Cancer

2年前

临床试验

Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas

Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

药物

Lutetium Lu 177 dotatate(Lutathera)

Temoporfin(Foscan)

Cisplatin(Platinol)

机构

Crinetics

资讯

BI 764532 T-Cell Engager Shows Promise in DLL3-Positive Neuroendocrine Carcinomas with 29% Response Rate

DLL3-Targeted Therapies Show Promise in Neuroendocrine Prostate Cancer

ABD-147 and PT217 Receive FDA Orphan Drug Designations for Neuroendocrine Carcinoma Treatment